{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:25:53Z","timestamp":1789349153301,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd008872","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,11,9]],"date-time":"2011-11-09T00:00:00Z","timestamp":1320796800000}}],"reference-count":216,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008872.pub2","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T18:21:02Z","timestamp":1320171662000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)"],"prefix":"10.1002","author":[{"given":"Alexandra N","family":"Colebatch","sequence":"first","affiliation":[{"name":"Southampton General Hospital; Department of Rheumatology; Tremona Road Southampton; Consultant Rheumatologist Yeovil District Hospital, Somerset Hampshire UK SO16 6YD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L","family":"Marks","sequence":"additional","affiliation":[{"name":"Southampton General Hospital; Department of Rheumatology; Tremona Road Southampton Hampshire UK SO16 6YD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Edwards","sequence":"additional","affiliation":[{"name":"Southampton General Hospital; Department of Rheumatology; Tremona Road Southampton Hampshire UK SO16 6YD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,9]]},"reference":[{"key":"10.1002\/14651858.CD008872.pub2-BIB0001|cit1","first-page":"203","article-title":"Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"21","author":"Anaya","year":"1994","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0002|cit2","first-page":"51","article-title":"Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate","volume":"21","author":"Carroll","year":"1994","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0049-0172(87)90021-7","article-title":"Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate","volume":"16","author":"Carson","year":"1987","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/rheumatology\/34.5.421","article-title":"Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients","volume":"34","author":"Combe","year":"1995","journal-title":"British Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0005|cit5","first-page":"2092","article-title":"Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis","volume":"29","author":"Fathi","year":"2002","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0006|cit6","first-page":"1628","article-title":"Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis","volume":"17","author":"Furst","year":"1990","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02230334","article-title":"Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate","volume":"15","author":"Franck","year":"1996","journal-title":"Clinical Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/art.1780331102","article-title":"Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis","volume":"33","author":"Fries","year":"1990","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.rhu.0000260526.29331.a8","article-title":"Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis","volume":"13","author":"Ideguchi","year":"2007","journal-title":"Journal of Clinical Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0010|cit10","first-page":"2539","article-title":"Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"26","author":"Karim","year":"1999","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.1989.00390030137027","article-title":"Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis","volume":"149","author":"McKendry","year":"1989","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0012|cit12","first-page":"1850","article-title":"Adverse effects of low dose methotrexate therapy in rheumatoid arthritis","volume":"20","author":"McKendry","year":"1993","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1177\/0091270009338939","article-title":"Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"49","author":"Schwartz","year":"2009","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/ard.52.8.613","article-title":"Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis","volume":"52","author":"Seideman","year":"1993","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/art.1780341207","article-title":"Aspirin alters methotrexate disposition in rheumatoid arthritis patients","volume":"34","author":"Stewart","year":"1991","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/03009740510017977","article-title":"Urinary excretion of \u03b1-GST and albumin in rheumatoid arthritis patients treated with methotrexate or other DMARDs alone or in combination with NSAIDs","volume":"34","author":"Svendsen","year":"2005","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00296-006-0261-x","article-title":"Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis","volume":"27","author":"S\u00e1nchez","year":"2007","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0018|cit18","first-page":"387","article-title":"Side effects of methotrexate treatment in patients with rheumatoid arthritis","volume":"17","author":"\u015awierkot","year":"2008","journal-title":"Advances in Clinical and Experimental Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0019|cit19","first-page":"1356","article-title":"Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs?","volume":"15","author":"Ahern","year":"1988","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0020|cit20","first-page":"72","article-title":"Efficacy of methotrexate in rheumatoid arthritis","volume":"23","author":"Ali","year":"1997","journal-title":"Bangladesh Medical Research Council Bulletin"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0021|cit21","first-page":"3","article-title":"Methotrexate in rheumatoid arthritis: a 2 year experience at a university hospital in Pakistan","volume":"48","author":"Ali","year":"1998","journal-title":"Journal of the Pakistan Medical Association"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/030097401753180318","article-title":"Clinical investigation of methotrexate in the treatment of ankylosing spondylitis","volume":"30","author":"Altan","year":"2001","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10067-005-1158-x","article-title":"Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms","volume":"25","author":"Ayhan-Ardic","year":"2006","journal-title":"Clinical Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0024|cit24","first-page":"1765","article-title":"The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors","volume":"34","author":"Benito-Garcia","year":"2007","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/41.9.1008","article-title":"Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: A randomized, controlled comparison with placebo and naproxen","volume":"41","author":"Bensen","year":"2002","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archinternmed.2007.107","article-title":"Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis","volume":"168","author":"Bernatsky","year":"2008","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0027|cit27","first-page":"473","article-title":"Methotrexate in the therapy of rheumatoid arthritis. Results in 30 patients","volume":"83","author":"Biasi","year":"1992","journal-title":"Recenti Progressi in Medicina"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0028|cit28","first-page":"472","article-title":"Methotrexate therapy in elderly onset rheumatoid arthritis","volume":"86","author":"Biasi","year":"1995","journal-title":"Recenti Progressi in Medicina"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s100670050027","article-title":"Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study","volume":"19","author":"Biasi","year":"2000","journal-title":"Clinical Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0030|cit30","first-page":"1171","article-title":"Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions","volume":"27","author":"Blomqvist","year":"2000","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0031|cit31","first-page":"503","article-title":"Low-dose weekly oral methotrexate therapy for inflammatory arthritis","volume":"5","author":"Boh","year":"1986","journal-title":"Clinical Pharmacy"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0033|cit33","first-page":"177","article-title":"Observations on longterm results of methotrexate in rheumatoid arthritis patients in Kashmir","volume":"7","author":"Buhroo","year":"2000","journal-title":"JK Practitioner"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0034|cit34","first-page":"1906","article-title":"Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD","volume":"31","author":"Cannon","year":"2004","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0035|cit35","first-page":"2099","article-title":"\"5D\" outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial disease modifying antirheumatic drug therapy","volume":"29","author":"Capell","year":"2002","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0036|cit36","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chavravarty","year":"2005","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.1780400906","article-title":"Rheumatoid arthritis and the risk of malignancy","volume":"40","author":"Cibere","year":"1997","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","article-title":"Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group","volume":"44","author":"Cohen","year":"2001","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0039|cit39","first-page":"1104","article-title":"Methotrexate in severe ankylosing spondylitis: an open study","volume":"22","author":"Creemers","year":"1995","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/rheumatology\/41.3.262","article-title":"Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: A prospective study incorporating HRCT scanning and pulmonary function tests","volume":"41","author":"Dawson","year":"2002","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0042|cit42","first-page":"1189","article-title":"Low-dose methotrexate may cause air trapping in patients with rheumatoid arthritis","volume":"151","author":"Dayton","year":"1995","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/ard.54.11.881","article-title":"Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients","volume":"54","author":"Mata","year":"1995","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0011-393X(97)80034-3","article-title":"Disposition and clinical efficacy of methotrexate in patients with rheumatoid arthritis following weekly, low, intramuscular dosing: A pilot study","volume":"58","author":"Desoky","year":"1997","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7326\/0003-4819-148-2-200801150-00192","article-title":"Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis","volume":"148","author":"Donahue","year":"2008","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1055\/s-2008-1027173","article-title":"Current trends in the therapy for ankylosing spondylitis - Results of a patient survey","volume":"33","author":"Feldtkeller","year":"2008","journal-title":"Aktuelle Rheumatologie"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.1780351003","article-title":"Use of short-term efficacy\/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials","volume":"35","author":"Felson","year":"1992","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/rheumatology\/41.8.892","article-title":"Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years","volume":"41","author":"Ferraccioli","year":"2002","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/art.1780360303","article-title":"The relative toxicity of disease-modifying antirheumatic drugs","volume":"36","author":"Fries","year":"1993","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/jps.2600790907","article-title":"Effect of aspirin and sulindac on methotrexate clearance","volume":"79","author":"Furst","year":"1990","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0051|cit51","first-page":"460","article-title":"Treatment of rheumatoid arthritis with higher dose intravenous methotrexate","volume":"17","author":"Gabriel","year":"1990","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0052|cit52","first-page":"2337","article-title":"Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study","volume":"26","author":"Galindo-Rodriguez","year":"1999","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0053|cit53","first-page":"951","article-title":"A randomized controlled clinical trial of actarit in the treatment of rheumatoid arthritis","volume":"37","author":"Gao","year":"2002","journal-title":"Chinese Pharmaceutical Journal"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0054|cit54","first-page":"153","article-title":"Low dose treatment with methotrexate-adverse drug reactions survey","volume":"139","author":"Getov","year":"2000","journal-title":"Bollettino Chimico Farmaceutico"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1185\/030079906X80341","article-title":"Real-world utilization of DMARDs and biologics in rheumatoid arthritis: The RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study","volume":"22","author":"Gibofsky","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.clinthera.2007.06.016","article-title":"Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: A 12-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"29","author":"Gibofsky","year":"2007","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archinternmed.2007.59","article-title":"Progressive preclinical interstitial lung disease in rheumatoid arthritis","volume":"168","author":"Gochuico","year":"2008","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0058|cit58","first-page":"1568","article-title":"Efficacy of methotrexate in ankylosing spondylitis: A randomized, double blind, placebo controlled trial","volume":"31","author":"Gonzalez-Lopez","year":"2004","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/ard.60.3.214","article-title":"Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery","volume":"60","author":"Grennan","year":"2001","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0049-0172(83)90014-8","article-title":"Low dose oral methotrexate in rheumatoid arthritis: An uncontrolled trial and review of the literature","volume":"12","author":"Groff","year":"1983","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0061|cit61","first-page":"984","article-title":"Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis","volume":"23","author":"Gumbhir-Shah","year":"1996","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","article-title":"No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: A 16-week open-label trial","volume":"66","author":"Haibel","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1345\/aph.1E044","article-title":"Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients","volume":"38","author":"Hartmann","year":"2004","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0064|cit64","first-page":"472","article-title":"Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions","volume":"35","author":"Helliwell","year":"2008","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0065|cit65","first-page":"2325","article-title":"Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis","volume":"30","author":"Hoekstra","year":"2003","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.62.5.423","article-title":"Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis","volume":"62","author":"Hoekstra","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0067|cit67","first-page":"845","article-title":"Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis","volume":"24","author":"H\u00fcbner","year":"1997","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/BF02229648","article-title":"The frequency and clinical characteristics of methotrexate (MTX) oral toxicity in rheumatoid arthritis (RA): A masked and controlled study","volume":"15","author":"Ince","year":"1996","journal-title":"Clinical Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1099-081X(199804)19:3<163::AID-BDD82>3.0.CO;2-L","article-title":"The effects of non-steroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis","volume":"19","author":"Iqbal","year":"1998","journal-title":"Biopharmaceutics and Drug Disposition"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00296-009-1057-6","article-title":"Efficacy of SLZ and MTX (alone or combination) on the treatment of active sacroiliitis in early AS","volume":"29","author":"Kabasakal","year":"2009","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00296-004-0469-6","article-title":"Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases","volume":"24","author":"Kargili","year":"2004","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s003930050181","article-title":"Long-term application of disease modifying antirheumatic drugs (DMARD). A single-center, observational study of 1681 patients with rheumatoid arthritis (RA)","volume":"58","author":"Keysser","year":"1999","journal-title":"Zeitschrift fur Rheumatologie"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0073|cit73","first-page":"61","article-title":"The treatment of inflammatory arthritis with methotrexate in clinical practice: Treatment duration and incidence of adverse drug reactions","volume":"44","author":"Kinder","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.60.4.327","article-title":"A prospective study of renal disease in patients with early rheumatoid arthritis","volume":"60","author":"Koseki","year":"2001","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7","article-title":"Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis","volume":"43","author":"Krause","year":"2000","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0076|cit76","first-page":"38","article-title":"Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy","volume":"22","author":"Kremer","year":"1995","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0077|cit77","first-page":"2072","article-title":"The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg","volume":"22","author":"Kremer","year":"1995","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0078|cit78","first-page":"459","article-title":"Significant changes in serum AST across hepatic histological biopsy grades: Prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis","volume":"23","author":"Kremer","year":"1996","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0079|cit79","first-page":"261","article-title":"Safety of methotrexate in rheumatoid arthritis: A retrospective cohort study in clinical practice","volume":"58","author":"Montagna","year":"2006","journal-title":"Reumatismo"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.23913","article-title":"Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis","volume":"59","author":"Lacaille","year":"2008","journal-title":"Arthritis Care and Research"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0081|cit81","first-page":"232","article-title":"Transient increase of aminotransferases in RA patients treated with methotrexate","volume":"52","author":"Lacki","year":"1993","journal-title":"Zeitschrift fur Rheumatologie"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ajg.2008.149","article-title":"How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial","volume":"104","author":"Laine","year":"2009","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1445-5994.2008.01737.x","article-title":"Treatment-induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis","volume":"39","author":"Lester","year":"2009","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0084|cit84","first-page":"10","article-title":"Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis","volume":"24","author":"Lightfoot","year":"1997","journal-title":"The Journal of Rheumatology. Supplement"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/rheumatology\/keh685","article-title":"Methotrexate-induced pancytopenia: Serious and under-reported? Our experience of 25 cases in 5 years","volume":"44","author":"Lim","year":"2005","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0086|cit86","first-page":"881","article-title":"Leflunomide in psoriatic arthritis: A retrospective study of discontinuation rate in daily clinical practice compared with methotrexate","volume":"25","author":"Malesci","year":"2007","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0087|cit87","first-page":"979","article-title":"Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs","volume":"35","author":"Malysheva","year":"2008","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0088|cit88","first-page":"248","article-title":"Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: A population-based incidence cohort of patients with rheumatoid arthritis","volume":"33","author":"Maradit-Kremers","year":"2006","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1297-319X(02)00396-2","article-title":"Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis","volume":"69","author":"Marguerie","year":"2002","journal-title":"Joint, Bone, Spine: Revue du Rhumatisme"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0090|cit90","first-page":"28","article-title":"Antirheumatic therapeutic models in rheumatic diseases and changes in the upper gastrointestinal tract","volume":"14","author":"Marinchev","year":"2006","journal-title":"Revmatologiia"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0091|cit91","first-page":"249","article-title":"Lack of immunosuppressive effect of low-dose oral methotrexate on lymphocytes in rheumatoid arthritis","volume":"11","author":"Martinez-Osuna","year":"1993","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/598331","article-title":"Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis","volume":"48","author":"McDonald","year":"2009","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/rheumatology\/41.7.741","article-title":"Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density","volume":"41","author":"Minaur","year":"2002","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0094|cit94","first-page":"704","article-title":"Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice","volume":"19","author":"Morand","year":"1992","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0095|cit95","first-page":"2214","article-title":"Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died","volume":"22","author":"Myllykangas-Luosuj\u00e4rvi","year":"1995","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0096|cit96","first-page":"1090","article-title":"Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: A nested, case-control study","volume":"59","author":"Nadareishvili","year":"2008","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/s101650200021","article-title":"Usefulness of actarit in elderly rheumatoid arthritis","volume":"12","author":"Nagaoka","year":"2002","journal-title":"Modern Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0098|cit98","first-page":"260","article-title":"Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis","volume":"24","author":"Nagashima","year":"2006","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/BF03041273","article-title":"Life table analysis of treatment episodes with disease-modifying anti-rheumatic drugs in rheumatoid arthritis","volume":"9","author":"Nakazaki","year":"1999","journal-title":"Japanese Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/BF02208152","article-title":"Experience with low-dose methotrexate: Toxicity, tolerability and effect on conventional patterns of drug therapy for inflammatory arthritis","volume":"14","author":"Nisar","year":"1995","journal-title":"Clinical Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0101|cit101","first-page":"49","article-title":"Methotrexate in rheumatoid arthritis","volume":"15","author":"Nolla","year":"1988","journal-title":"Revista Espanola de Reumatologia"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0102|cit102","first-page":"3141","article-title":"Microalbuminuria in patients with rheumatoid arthritis","volume":"158","author":"Nordin","year":"1996","journal-title":"Ugeskrift for Laeger"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications","volume":"334","author":"O'Dell","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0104|cit104","first-page":"217","article-title":"Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study","volume":"83","author":"Osiri","year":"2000","journal-title":"Journal of the Medical Association of Thailand"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0105|cit105","first-page":"261","article-title":"Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study","volume":"29","author":"Papadopoulos","year":"2002","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.61.10.889","article-title":"Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis","volume":"61","author":"Peltomaa","year":"2002","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1590\/S0482-50042009000400003","article-title":"National recommendations based on scientific evidence and opinions of experts on the use of methotrexate in rheumatic disorders, especially in rheumatoid arthritis. Results of the 3E Initiative from Brazil","volume":"49","author":"Pereira","year":"2009","journal-title":"Revista Brasileira de Reumatologia"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","article-title":"Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis","volume":"52","author":"Prodanovich","year":"2005","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1002\/art.24040","article-title":"Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages","volume":"58","author":"Reiss","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1753-5174.2009.00019.x","article-title":"Drugs used in the treatment of rheumatoid arthritis: Relationship between current use and cardiovascular risk factors","volume":"2","author":"Rho","year":"2009","journal-title":"Archives of Drug Information"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s00508-009-1264-x","article-title":"Rationale for bone marrow examination in patients with inflammatory rheumatic diseases","volume":"121","author":"Richter","year":"2009","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0112|cit112","first-page":"1297","article-title":"Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate","volume":"20","author":"Rooney","year":"1993","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/030097402320817040","article-title":"Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy","volume":"31","author":"Ros","year":"2002","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0114|cit114","first-page":"911","article-title":"Seroprevalence of Helicobacter pylori in rheumatoid arthritis and its relationship to pharmacotherapy","volume":"50","author":"Ryb\u00e1r","year":"2004","journal-title":"Vnit\u0159n\u00ed L\u00e9ka\u0159stv\u00ed"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0115|cit115","first-page":"69","article-title":"Plasma from rheumatoid patients taking low dose methotrexate enhances platelet aggregation","volume":"111","author":"Saeed","year":"2002","journal-title":"Research Communications in Molecular Pathology & Pharmacology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0116|cit116","first-page":"23","article-title":"A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis","volume":"13","author":"Salaffi","year":"1995","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/030097400750002021","article-title":"Methotrexate in the treatment of ankylosing spondylitis","volume":"29","author":"Sampaio-Barros","year":"2000","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10067-007-0787-7","article-title":"The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate","volume":"27","author":"Scarpa","year":"2008","journal-title":"Clinical Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0119|cit119","first-page":"944","article-title":"Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs","volume":"20","author":"Scherak","year":"1993","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/030097499750042263","article-title":"Leflunomide versus methotrexate: a comparison of the European and American experience","volume":"112","author":"Schiff","year":"1999","journal-title":"Scandinavian Journal of Rheumatology. Supplement"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard.2006.061820","article-title":"Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study","volume":"66","author":"Schoels","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1177\/00912700122012616","article-title":"Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients","volume":"41","author":"Schwartz","year":"2001","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0123|cit123","first-page":"188","article-title":"Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis","volume":"18","author":"Singh","year":"1991","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0124|cit124","first-page":"860","article-title":"Methotrexate in psoriatic arthritis","volume":"42","author":"Singh","year":"1994","journal-title":"Journal of the Association of Physicians of India"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0125|cit125","first-page":"1008","article-title":"Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis","volume":"17","author":"Skeith","year":"1990","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jnci\/djj004","article-title":"Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype","volume":"98","author":"Smedby","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Care and Research"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0128|cit128","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten","year":"2008","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/clpt.1990.69","article-title":"Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis","volume":"47","author":"Stewart","year":"1990","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000190403","article-title":"Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: Effects of anti-rheumatoid arthritis drugs","volume":"78","author":"Sugimori","year":"2008","journal-title":"Digestion"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.amjmed.2004.02.032","article-title":"Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis","volume":"117","author":"Suissa","year":"2004","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.21806","article-title":"Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis","volume":"54","author":"Suissa","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/03009748609102072","article-title":"Low-dose methotrexate in rheumatoid arthritis: Effect and tolerance. An open trial and a double-blind randomized study","volume":"15","author":"Szanto","year":"1986","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0140-6736(86)90786-5","article-title":"Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen","volume":"1","author":"Thyss","year":"1986","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00290296","article-title":"Long-term experience with low dose methotrexate in rheumatoid arthritis","volume":"13","author":"Tishler","year":"1993","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00278469","article-title":"The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis","volume":"42","author":"Tracy","year":"1992","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2125.1994.tb05713.x","article-title":"Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis","volume":"37","author":"Tracy","year":"1994","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00393-003-0458-2","article-title":"Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases","volume":"62","author":"Ujfalussy","year":"2003","journal-title":"Zeitschrift fur Rheumatologie"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0091270005280100","article-title":"Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis","volume":"45","author":"Vakily","year":"2005","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/ard.61.12.1060","article-title":"Purine enzymes in patients with rheumatoid arthritis treated with methotrexate","volume":"61","author":"Ede","year":"2002","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/rheumatology\/39.12.1374","article-title":"Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis","volume":"39","author":"Jaarsveld","year":"2000","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1445-5994.2009.01800.x","article-title":"Methotrexate: Long-term safety and efficacy in an Australian consultant rheumatology practice","volume":"39","author":"Varatharajan","year":"2009","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1023\/A:1011909827909","article-title":"Polypharmacy among patients admitted to hospital with rheumatic diseases","volume":"23","author":"Vitkil","year":"2001","journal-title":"Pharmacy World and Science"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/00365529850171459","article-title":"Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients: Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer","volume":"33","author":"Voutilainen","year":"1998","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.10399","article-title":"Medication toxicity among patients with ankylosing spondylitis","volume":"47","author":"Ward","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0147|cit147","first-page":"334","article-title":"Methotrexate in rheumatoid arthritis: Effects on disease activity in a multicenter prospective study","volume":"18","author":"Weinblatt","year":"1991","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.1780280702","article-title":"Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial","volume":"28","author":"Williams","year":"1985","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0149|cit149","first-page":"314","article-title":"Methotrexate: a perspective of its use in the treatment of rheumatic diseases","volume":"100","author":"Willkens","year":"1982","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","article-title":"Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis","volume":"27","author":"Willkens","year":"1984","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0151|cit151","first-page":"994","article-title":"Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts","volume":"17","author":"Wolfe","year":"1990","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.2004.023408","article-title":"Long term safety of methotrexate in routine clinical care: Discontinuation is unusual and rarely the result of laboratory abnormalities","volume":"64","author":"Yazici","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0153|cit153","first-page":"111","article-title":"The diurnal variability of blood pressure in patients with hypertension and rheumatoid arthritis","volume":"55","author":"\u0158ih\u00e1\u010dek","year":"2009","journal-title":"Vnit\u0159n\u00ed L\u00e9ka\u0159stv\u00ed"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0154|cit154","first-page":"267","article-title":"Five year clinical evaluation of treatment efficacy with methotrexate in patients with rheumatoid arthritis","volume":"103","author":"\u015awierkot","year":"2000","journal-title":"Polskie Archiwum Medycyny Wewn\u0119trznej"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0155|cit155","first-page":"387","article-title":"Side effects of methotrexate treatment in patients with rheumatoid arthritis","volume":"17","author":"\u015awierkot","year":"2008","journal-title":"Advances in Clinical and Experimental Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0156|cit156","first-page":"213","article-title":"Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs","volume":"23","author":"Jiang","year":"2002","journal-title":"Chung-Hua Liu Hsing Ping Hsueh Tsa Chih (Chinese Journal of Epidemiology)"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0157|cit157","first-page":"929","article-title":"Cytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis","volume":"41","author":"Nakazaki","year":"2001","journal-title":"Ryumachi (Rheumatism)"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0158|cit158","first-page":"855","article-title":"Renal tubular dysfunction in patients with rheumatoid arthritis starting with low dose of methotrexate","volume":"110","author":"Wiland","year":"2003","journal-title":"Polskie Archiwum Medycyny Wew\u0119ntrznej"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0159|cit159","first-page":"460","article-title":"Methotrexate in conjunction with meloxicam for treating ankylosing spondylitis: a clinical observation of the efficacy and safety","volume":"23","author":"Xie","year":"2003","journal-title":"Di Yi Junyi Daxue Xuebao"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0160|cit160","first-page":"8186","article-title":"Long-term efficacy of methotrexate combined with meloxicam in treatment of morning stiffness, swelling of join and activity of thorax in patients with ankylosing spondylitis","volume":"8","author":"Xie","year":"2004","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0161|cit161","unstructured":"ACR Search Abstracts Online\/Program Planner http:\/\/www.rheumatology.org"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0162|cit162","unstructured":"AETNA Clinical Policy Bulletins Methotrexate (oral) http:\/\/aetna-health.healthline.com\/smartsource\/healthwisecontent\/Multum\/d00060a1#d00060a1-drugs July 2009"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0163|cit163","unstructured":"Australian Adverse Drug Reactions Bulletin http:\/\/www.tga.gov.au\/adr\/aadrb.htm"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0164|cit164","unstructured":"Australian Adverse Drug Reactions Bulletin Core product information for aspirin\/codeine combination analgesic http:\/\/www.tga.gov.au\/npmeds\/pi-codeine-aspirin.rtf February 2010"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0165|cit165","first-page":"5","article-title":"Social and economic impact of inflammatory arthritis","volume":"Spec No","author":"Bergman","year":"2006","journal-title":"Postgraduate Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0166|cit166","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3899\/jrheum.090153","article-title":"Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review","volume":"37","author":"Bourr\u00e9-Tessier","year":"2010","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0168|cit168","article-title":"Study quality assessment","volume-title":"Undertaking systematic reviews of research on effectiveness. CRD's guidance for those carrying out or commissioning reviews. Report 4","author":"Khan","year":"March 2001"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0169|cit169","unstructured":"Current Problems in Pharmacovigilance: MHRA http:\/\/www.mhra.gov.uk\/Publications\/Safetyguidance\/CurrentProblemsinPharmacovigilance\/index.htm"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0170|cit170","unstructured":"Drug Safety Research Unit http:\/\/www.dsru.org\/home.html"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0171|cit171","unstructured":"Drug Safety Update: MRHA http:\/\/www.mhra.gov.uk\/Publications\/Safetyguidance\/DrugSafetyUpdate\/index.htm"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0172|cit172","unstructured":"EMEA public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union http:\/\/www.ema.europa.eu\/pdfs\/human\/press\/pus\/35823405en.pdf 2005"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/bmj.332.7534.152","article-title":"Treatment of rheumatoid arthritis","volume":"332","author":"Emery","year":"2006","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0174|cit174","unstructured":"EPOC data collection checklist http:\/\/epoc.cochrane.org\/epoc-resources-review-authors"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0175|cit175","unstructured":"EULAR Abstract Archive http:\/\/www.abstracts2view.com\/eular\/"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0176|cit176","unstructured":"European Medicines\u00a0Evaluation Agency: European Public Assessment Reports http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d125"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0177|cit177","unstructured":"FDA alert. Information for healthcare professionals: valdecoxib http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124649.htm 2005"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.20","article-title":"Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis","volume":"34 Suppl 2","author":"Furst","year":"1995","journal-title":"British Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/ard.44.1.27","article-title":"Use of simple analgesics in rheumatoid arthritis","volume":"44","author":"Gibson","year":"1985","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0180|cit180","unstructured":"Goldshield Pharmaceuticals Limited Methotrexate 2.5mg tablets - electronic Medicines Compendium (eMC) http:\/\/www.medicines.org.uk\/EMC\/medicine\/22954\/SPC\/Methotrexate+2.5mg+Tablets\/ April 2010"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"GRADE Working Group","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0182|cit182","unstructured":"The Canadian Agency for Drugs and Technology in Health Grey Matters: a practical search tool for evidence-based medicine http:\/\/www.cadth.ca\/index.php\/en\/cadth\/products\/grey-matters July 2009"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00000441-195102000-00009","article-title":"Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis","volume":"221","author":"Gubner","year":"1951","journal-title":"The American Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0184|cit184","unstructured":"Hazardous Substances Data Bank Naproxen http:\/\/toxnet.nlm.nih.gov\/cgi-bin\/sis\/search\/r?dbs+hsdb:@term+@rn+22204-53-1 December 2009"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0185|cit185","unstructured":"Health Canada has asked Pfizer to suspend sales of its drug Bextra? and informs Canadians of new restrictions on the use of Celebrex\u00ae http:\/\/www.hc-sc.gc.ca\/ahc-asc\/media\/advisories-avis\/_2005\/2005_17-eng.php 2005"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0186|cit186","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]","author":"Higgins","year":"2009"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(83)90477-1","article-title":"Methotrexate therapy in rheumatoid arthritis: 15 years experience","volume":"12","author":"Hoffmeister","year":"1983","journal-title":"The American Journal of Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0188|cit188","unstructured":"Hospira UK Limited Package leaflet: information for the user Methotrexate 2.5mg tablets http:\/\/www.medicines.org.uk\/EMC\/medicine\/15727\/PIL\/Methotrexate+2.5+mg+Tablets\/ November 2010"},{"issue":"4","key":"10.1002\/14651858.CD008872.pub2-BIB0189|cit189","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008495","article-title":"Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis","author":"Katchamart","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.1780290702","article-title":"The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis","volume":"29","author":"Kremer","year":"1986","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/art.1780400533","article-title":"Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3. years","volume":"40","author":"Kremer","year":"1997","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"695","DOI":"10.7326\/0003-4819-134-8-200104170-00013","article-title":"Rational use of new and existing disease modifying agents in rheumatoid arthritis","volume":"138","author":"Kremer","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14740338.4.4.723","article-title":"Methotrexate pulmonary toxicity","volume":"4","author":"Lateef","year":"2005","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00006534-197606000-00009","article-title":"The synergistic effect of salicylates on methotrexate toxicity","volume":"57","author":"Mandel","year":"1976","journal-title":"Plastic and Reconstructive Surgery"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0196|cit196","unstructured":"MedWatch: the FDA Safety Information and Adverse Event Reporting Program http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/default.htm"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0197|cit197","unstructured":"Merck Announces Voluntary Worldwide Withdrawal of VIOXX\u00ae http:\/\/www.merck.com\/newsroom\/vioxx\/pdf\/vioxx_press_release_final.pdf. 2004"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0198|cit198","unstructured":"Lumiracoxib (Prexige): Suspension of Marketing Authorisations http:\/\/www.mhra.gov.uk\/Safetyinformation\/Safetywarningsalertsandrecalls\/Safetywarningsandmessagesformedicines\/CON2033073 2007"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.1780330102","article-title":"The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis","volume":"33","author":"Morgan","year":"1990","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.1780330620","article-title":"Biliary elimination of low-dose methotrexate in humans","volume":"33","author":"Nuernberg","year":"1990","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0201|cit201","unstructured":"Oregan Health Policy and Research Analgesics\/anesthetics, topical http:\/\/governor.oregon.gov\/OHPPR\/HRC\/docs\/Mats\/PDL\/6.22.10\/analg.anesth.top.apr10pl.pdf April 2010"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0202|cit202","unstructured":"Pharmaceutical Benefits Schedule Methotrexate Tablets. Consumer Medicine Information http:\/\/www.pbs.gov.au\/pbs\/pdf-viewer?pdf=%2Fmeds%2Fcmi%2Fhhcmetht20906.pdf September 2006"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0203|cit203","unstructured":"Pharmaceutical Management Agency Methoblastin \u00ae tablets http:\/\/www.medsafe.govt.nz\/Consumers\/cmi\/m\/methoblastin.pdf March 2010"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"14540","DOI":"10.1073\/pnas.95.24.14540","article-title":"Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion","volume":"95","author":"Pillinger","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0205|cit205","unstructured":"Review Manager http:\/\/ims.cochrane.org\/revman"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0206|cit206","first-page":"1164","article-title":"Methotrexate pneumonitis in rheumatoid arthritis: Potential risk factors. Four case reports and a review of the literature","volume":"14","author":"Searles","year":"1987","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0207|cit207","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie Actions and treatments explained. Methotrexate http:\/\/www.rhumatologie.asso.fr\/data\/fiche\/44.pdf August 2007"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0208|cit208","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Intervention. Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD008872.pub2-BIB0209|cit209","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000957","article-title":"Methotrexate for treating rheumatoid arthritis","author":"Suarez-Almazor","year":"1998","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0210|cit210","unstructured":"Regulator takes tough action on arthritis drugs (*amended) http:\/\/www.tga.gov.au\/media\/2005\/050225_cox2.htm 2005"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/01.STR.23.10.1400","article-title":"Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin","volume":"23","author":"Tohgi","year":"1992","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0212|cit212","first-page":"1017","article-title":"Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature","volume":"27","author":"Visser","year":"2009","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/ard.2003.011593","article-title":"Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis","volume":"63","author":"Wegrzyn","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0214|cit214","first-page":"238","article-title":"Longterm prospective study of methotrexate in rheumatoid arthritis: conclusions after 132 months of therapy","volume":"25","author":"Weinblatt","year":"1998","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008872.pub2-BIB0215|cit215","unstructured":"Wells GA Shea B O'Connell D Peterson J Welch V Losos M Tugwell P The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Department of Epidemiology and Community Medicine, University of Ottawa, Canada. URL: http:\/\/www.lri.ca\/programs\/ceu\/oxford.htm"},{"issue":"4","key":"10.1002\/14651858.CD008872.pub2-BIB0216|cit216","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003789.pub2","article-title":"Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis","author":"Wienecke","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008872.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T21:07:32Z","timestamp":1686431252000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008872.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,11,9]]},"references-count":216,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008872.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,9]]}}}